塞拉利昂2014年间经法匹拉韦(favipiravir,T-705)治疗的埃博拉病毒性疾病患者临床及病毒学特征

Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated with Favipiravir (T-705) - Sierra Leone, 2014
2017-02-28 12:30发表评论
作者:Bai, C.-Q, Mu, J.-S, Kargbo, D, Song, Y.-B, Niu, W.-K, Nie, W.-M, Kanu, A, Liu, W.-W, Wang, Y.-P, Dafae, F, Yan, T, Hu, Y, Deng, Y.-Q, Lu, H.-J, Yang, F, Zhang, X.-G, Sun, Y.g, Cao, Y.-X, Su, H.-X, Sun, Y, Liu, W.-S, Wang, C.-Y, Qian, J, Liu, L, Wang, H, Tong, Y.-G, Liu, Z.-Y, Chen, Y.-S, Wang, H.-Q, Kargbo, B, Gao, G.F, Jiang, J.-F.d
机构: 307医院
期刊: EMERG INFECT DIS2016年11月11期63卷

Background. During 2014-2015, an outbreak of Ebola virus disease (EVD) swept across parts of West Africa. No approved antiviral drugs are available for Ebola treatment currently. Methods. A retrospective clinical case series was performed for EVD patients in Sierra Leone-China Friendship Hospital. Patients with confirmed EVD were sequentially enrolled and treated with either World Health Organization (WHO)-recommended supportive therapy (control group) from 10 to 30 October, or treated with WHO-recommended therapy plus favipiravir (T-705) from 1 to 10 November 2014. Survival and virological characteristics were observed for 85 patients in the control group and 39 in the T-705 treatment group. Results. The overall survival rate in the T-705 treatment group was higher than that of the control group (56.4% [22/39] vs 35.3% [30/85]; P =. 027). Among the 35 patients who finished all designed endpoint observations, the survival rate in the T-705 treatment group (64.8% [11/17]) was higher than that of the control group (27.8% [5/18]). Furthermore, the average survival time of the treatment group (46.9 ± 5.6 days) was longer than that of the control group (28.9 ± 4.7 days). Most symptoms of patients in the treatment group improved significantly. Additionally, 52.9% of patients who received T-705 had a >100-fold viral load reduction, compared with only 16.7% of patients in the control group. Conclusions. Treatment of EVD with T-705 was associated with prolonged survival and markedly reduced viral load, which makes a compelling case for further randomized controlled trials of T-705 for treating EVD. © The Author 2016.

通讯机构:No. 307 Hospital, China
学科代码:感染病学   关键词:塞拉利昂 间经法匹拉韦 埃博拉病毒性疾病患者 ,中国作者重要发表 爱思唯尔医学网, Elseviermed
来源: Scopus
Scopus介绍:Scopus 于2004年11月正式推出,是目前全球规模最大的文摘和引文数据库。Scopus涵盖了由5000多家出版商出版发行的科技、医学和社会科学方面的18,000多种期刊,其中同行评审期刊16,500多种。相对于其他单一的文摘索引数据库而言,Scopus的内容更加全面,学科更加广泛,特别是在获取欧洲及亚太地区的文献方面,用户可检索出更多的文献数量。通过Scopus,用户可以检索到1823年以来的近4000万条摘要和题录信息,以及1996年以来所引用的参考文献。数据每日更新。 马上访问Scopus网站http://www.scopus.com/
顶一下(0
您可能感兴趣的文章
发表评论网友评论(0)
发表评论
登录后方可发表评论,点击此处登录